Facilitating Biopharma Continuous Manufacturing

News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, March 2022
Volume 2022 eBook
Issue 1
Pages: 52-54

USP is advancing understanding and developing guidance and standards to assist industry in implementing continuous manufacturing.

Rawpixel.com/Stock.adobe.com

Rawpixel.com/Stock.adobe.com

Manufacturers, regulators, and other industry organizations are aiming to advance biopharmaceutical continuous manufacturing and to connect upstream and downstream into fully continuous processes. The United States Pharmacopeial Convention (USP), a nonprofit organization known for developing standards for quality, is actively involved in facilitating implementation of continuous manufacturing in the bio/pharmaceutical industry. Pharmaceutical Technology spoke with John Kokai-Kun, director, External Scientific Collaboration at USP about these efforts.

Read “Facilitating Biopharma Continuous Manufacturing” in Pharmaceutical Technology’s Quality and Regulatory Sourcebook Ebook.

Article details:

Pharmaceutical Technology
eBook: Quality and Regulatory Sourcebook
March 2022
Pages: 52-54

Citation

When referring to this article, please cite it as J. Markarian, “Facilitating Biopharma Continuous Manufacturing,” Pharmaceutical Technology’s Quality and Regulatory Sourcebook eBook (March 2022).

Articles in this issue
Common FDA 483 Observations for Combination Products
Common FDA 483 Observations for Combination Products
Facilitating Biopharma Continuous Manufacturing
Facilitating Biopharma Continuous Manufacturing
Warut/Stock.adobe.com – Testing cleanroom garments while in use and during daily cleanroom operations is vital for contamination control.
In-Use Testing of Cleanroom Garments
How a Lack of Critical Thinking is Hindering Regulatory Compliance
How a Lack of Critical Thinking is Hindering Regulatory Compliance
A Method Validation Framework for Combination Products
A Method Validation Framework for Combination Products
Contextualizing Computer Validation
Contextualizing Computer Validation
Supply Chain Considerations for Ensuring Quality
Supply Chain Considerations for Ensuring Quality
DSCSA’s Next Big Hurdle
DSCSA’s Next Big Hurdle
Remote Inspections - Lessons Learned
Remote Inspections - Lessons Learned
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

EMA Recommends Five New Medicines for Approval

Patrick Lavery
March 28th 2025
Article

Three of the five are biosimilars, and seven additional medicines received recommendations for indication extensions.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Issues Warning Letter to Aspen Biopharma Labs for API Manufacturing Deviations

Feliza Mirasol
March 27th 2025
Article

In the latest of a series of warning letters to India-based API manufacturers, FDA issued a warning letter to Aspen for deviations in CGMP in the production of APIs.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

BIO Survey: Tariffs May Reduce Access, Delay Innovation, Create Red Tape

Patrick Lavery
March 27th 2025
Article

The Biotechnology Innovation Organization’s new membership survey said that 90% of US biotech companies rely on imported components for at least half of their FDA-approved products.